Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000932471-25-001051
Filing Date
2025-07-29
Accepted
2025-07-29 14:41:06
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 4549
  Complete submission text file 0000932471-25-001051.txt   6424
Mailing Address PO BOX 2600 V26 VALLEY FORGE PA 19482-2600
Business Address 100 VANGUARD BLVD MALVERN PA 19355 6106691000
VANGUARD GROUP INC (Filed by) CIK: 0000102909 (see all company filings)

EIN.: 231945930 | State of Incorp.: PA | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Subject) CIK: 0001438533 (see all company filings)

EIN.: 262383102 | State of Incorp.: CA | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-87088 | Film No.: 251160687
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)